AI and Biotech Join Forces to Revolutionize Drug Discovery and Gene Editing

Modern biotechnology companies like Insilico Medicine and GenEditBio are leveraging AI to address the persistent challenge of untreated rare diseases. Speaking at Web Summit Qatar, Insilico's President, Alex Aliper, emphasized the company's goal of developing 'pharmaceutical superintelligence'. The company recently launched its MMAI Gym, aimed at training large language models to autonomously tackle diverse drug discovery tasks. Aliper stressed the need for advanced AI systems to mitigate labor shortages, particularly with thousands of diseases lacking effective treatments.

• Insilico Medicine has developed a platform that processes biological, chemical, and clinical data to hypothesize disease targets and candidate molecules, aiming to reduce drug discovery time and cost. They demonstrated this by identifying potential ALS treatments from existing drugs.
• GenEditBio is innovating within the gene editing field, aiming for targeted, in vivo delivery using their proprietary 'engineered protein delivery vehicle' (ePDV). Their NanoGalaxy platform utilizes AI to optimize delivery vehicles for specific tissue targets, minimizing immune responses.
• Both companies highlight the critical role of AI in processing complex biological data and foresee digital twins as the future for virtual clinical trials. However, they acknowledge a significant data gap, particularly regarding diverse human biology data sets.
• The article also touches on broader biotech challenges, like the need for greater approval rates for new drugs by regulatory bodies like the FDA.

GenEditBio recently received approval to trial CRISPR therapy for corneal dystrophy, underscoring the potential of AI-driven biotech innovations.